NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

EYPT

EyePoint Pharmaceuticals Inc

Jul 11 • 04:00PM ET

10.36

Dollar change -0.70
Percentage change -6.33	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN ALNY VRTX NBIX BMRN IONS SAGE RARE AGIO BLUE

| Held by: IWM VTI VXF IWN VTWO IWC XPH VHT ITOT PINK

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.41	Insider Own	13.08%	Shs Outstand	68.81M	Perf Week	6.58%
Market Cap	712.89M	Forward P/E	-	EPS next Y	-2.93	Insider Trans	0.22%	Shs Float	59.81M	Perf Month	12.49%
Enterprise Value	418.78M	PEG	-	EPS next Q	-0.82	Inst Own	98.22%	Short Float	11.59%	Perf Quarter	126.70%
Income	-146.78M	P/S	12.72	EPS this Y	-31.19%	Inst Trans	-0.35%	Short Ratio	8.59	Perf Half Y	12.36%
Sales	56.04M	P/B	2.39	EPS next Y	3.69%	ROA	-42.43%	Short Interest	6.93M	Perf YTD	39.06%
Book/sh	4.34	P/C	2.24	EPS next 5Y	-1.73%	ROE	-53.54%	52W High	13.98 -25.92%	Perf Year	18.13%
Cash/sh	4.62	P/FCF	-	EPS past 3/5Y	-4.60% 15.65%	ROIC	-45.77%	52W Low	3.91 164.96%	Perf 3Y	32.99%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	5.42% 16.27%	Gross Margin	93.29%	Volatility	8.10% 8.24%	Perf 5Y	43.89%
Dividend TTM	-	EV/Sales	7.47	EPS Y/Y TTM	-31.81%	Oper. Margin	-287.94%	ATR (14)	0.75	Perf 10Y	-72.66%
Dividend Ex-Date	-	Quick Ratio	7.79	Sales Y/Y TTM	12.04%	Profit Margin	-261.91%	RSI (14)	61.62	Recom	1.08
Dividend Gr. 3/5Y	- -	Current Ratio	7.85	EPS Q/Q	-17.06%	SMA20	8.42%	Beta	1.76	Target Price	31.75
Payout	-	Debt/Eq	0.08	Sales Q/Q	109.29%	SMA50	30.36%	Rel Volume	1.12	Prev Close	11.06
Employees	165	LT Debt/Eq	0.07	Earnings	May 07 BMO	SMA200	31.70%	Avg Volume	807.62K	Price	10.36
IPO	Jan 27, 2005	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.47% 210.52%	Trades		Volume	903,298	Change	-6.33%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-25	Initiated	RBC Capital Mkts	Outperform	$28
Jan-07-25	Initiated	Citigroup	Buy	$33
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-28-24	Initiated	Jefferies	Buy	$15
Jan-22-24	Initiated	JP Morgan	Overweight	$35
Nov-02-23	Initiated	Mizuho	Buy	$20
Apr-21-23	Initiated	Robert W. Baird	Outperform	$33
Jul-07-22	Initiated	Chardan Capital Markets	Buy	$21
Mar-01-21	Initiated	Cowen	Outperform	$25
Jan-28-21	Initiated	Cantor Fitzgerald	Overweight	$22
Apr-06-20	Downgrade	B. Riley FBR	Buy → Neutral	$4 → $1
Nov-04-19	Resumed	Laidlaw	Buy	$5
Sep-12-19	Initiated	Guggenheim	Buy

Show Previous Ratings

Jun-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 11:54AM	Breakout Momentum Plays You May Not Know About (MarketBeat) +8.36%
May-28-25 04:01PM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire) +18.12%
May-27-25 07:00AM	EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU for Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
May-16-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +7.17%
07:00AM	Loading…
May-13-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
May-07-25 02:49PM	Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum (Seeking Alpha)
02:49PM	EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:25AM	EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:22AM	EyePoint Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Apr-30-25 07:00AM	EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire)
Apr-16-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-27-25 07:00AM	EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference (GlobeNewswire)
07:00AM	Loading…
Mar-17-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-06-25 02:14AM	Q4 2024 EyePoint Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:06AM	EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highlights: Navigating Challenges ... (GuruFocus.com)
Mar-05-25 09:30AM	EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks) +8.22%
08:25AM	EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:34AM	EyePoint Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Mar-04-25 07:17AM	Earnings To Watch: EyePoint Pharmaceuticals Inc (EYPT) Reports Q4 2024 Result (GuruFocus.com) +6.29%
07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Feb-26-25 07:00AM	EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025 (GlobeNewswire)
Feb-25-25 07:00AM	EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-17-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-05-25 07:00AM	EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema Meeting Primary and Secondary Endpoints (GlobeNewswire)
Jan-30-25 07:00AM	EyePoint to Present at Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-16-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.46%
07:00AM	Loading…
Jan-13-25 07:00AM	EyePoint Provides Company Update and Anticipated Development Milestones for 2025 (GlobeNewswire) -7.07%
Jan-08-25 07:00AM	EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors (GlobeNewswire)
Dec-17-24 07:25AM	EyePoint reports inducement grants under NASDAQ listing rule (TipRanks) +5.39%
07:00AM	EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-05-24 07:06AM	EyePoint doses first patient in second Phase 3 LUCIA clinical trial (TipRanks)
Dec-04-24 07:00AM	EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU for the Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
Nov-18-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -6.43%
Nov-13-24 09:55AM	Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High? (Zacks)
Nov-12-24 06:45AM	EyePoint price target lowered to $33 from $38 at Baird (TipRanks) -7.42%
Nov-07-24 08:35AM	EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:37AM	EyePoint Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Nov-04-24 07:00AM	EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Oct-31-24 04:00PM	EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares (GlobeNewswire)
Oct-29-24 09:47PM	EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering (GlobeNewswire)
04:49AM	EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock? (Zacks)
Oct-28-24 05:14PM	EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire) +27.58%
12:16PM	EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss (Benzinga)
07:00AM	EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema (GlobeNewswire)
Oct-24-24 07:00AM	EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
Oct-23-24 09:20AM	ANI Pharmaceuticals price target raised to $62 from $60 at Truist (TipRanks) -7.35%
Oct-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +14.17%
Sep-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-04-24 07:00AM	EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors (GlobeNewswire)
Aug-27-24 07:00AM	EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Aug-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-24 07:00AM	EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire) +5.90%
Aug-07-24 08:15AM	EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:09AM	EyePoint Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Jul-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-15-24 08:00AM	Milestone Pharmaceuticals Refreshes Board of Directors (GlobeNewswire)
Jun-26-24 08:00AM	EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024 (GlobeNewswire)
08:00AM	EyePoint Pharmaceuticals to Highlight DURAVYU (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024 (GlobeNewswire)
Jun-18-24 07:00AM	EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024 (GlobeNewswire)
Jun-17-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-05-24 07:00AM	EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire) +6.18%
02:35AM	Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT) (GuruFocus.com)
May-17-24 02:34AM	Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT) (GuruFocus.com) -5.43%
May-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-10-24 02:34PM	EyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite Challenges (GuruFocus.com)
May-08-24 01:54PM	EYPT Stock Earnings: EyePoint Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
10:48AM	Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating (MT Newswires)
07:23AM	EyePoint Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
May-07-24 09:32AM	Chardan Research Adjusts EyePoint Pharmaceuticals' PT to $28 From $39 After Data From PAVIA Study of Duravyu Disappoint; Keeps Buy Rating (MT Newswires) +5.98%
May-06-24 11:00AM	Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday? (Benzinga) -43.26%
08:42AM	EyePoint Pharmaceuticals Shares Fall After Diabetes Drug Fails to Meet Primary Endpoint (MT Newswires)
07:00AM	EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU in Non-Proliferative Diabetic Retinopathy (GlobeNewswire)
Apr-23-24 01:21PM	Hedge Fund and Insider Trading News: David Tepper, Ray Dalio, RA Capital Management, Millennium Management, Biohaven Ltd (BHVN), EyePoint Pharmaceuticals Inc. (EYPT), and More (Insider Monkey)
Apr-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-24 07:00AM	EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists (GlobeNewswire)
Mar-18-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-15-24 01:00PM	5 Growth Stocks Under $50 for March 2024 (Investopedia)
Mar-08-24 09:31AM	EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-07-24 09:39PM	Q4 2023 EyePoint Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
01:25PM	EyePoint Pharmaceuticals Inc (EYPT) Reports Growth Amidst Strategic Shifts in Q4 and Full-Year 2023 (GuruFocus.com)
12:53PM	EYPT Stock Earnings: EyePoint Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
09:30AM	Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics (Zacks)
07:20AM	EyePoint Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Mar-04-24 07:00AM	EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer (GlobeNewswire) -7.46%
Feb-29-24 10:00AM	Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know (Zacks)
08:50AM	Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep going (Zacks)
07:00AM	EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024 (GlobeNewswire)
04:19AM	20 Countries With Worst Vision Problems (Insider Monkey)
Feb-27-24 07:00AM	EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire) +7.98%
Feb-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-15-24 12:00PM	Are You Looking for a Top Momentum Pick? Why EyePoint Pharmaceuticals (EYPT) is a Great Choice (Zacks)

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zaderej Karen L.	Director	Jul 11 '25	Option Exercise	0.00	2,000	0	38,500	Jul 11 04:07 PM
Lurker Nancy	Director	Jul 10 '25	Option Exercise	0.00	11,111	0	216,547	Jul 11 04:06 PM
Duker Jay S.	President and CEO	Jul 10 '25	Option Exercise	0.00	16,667	0	17,653	Jul 11 04:06 PM
Elston George	Chief Financial Officer	May 25 '25	Option Exercise	0.00	7,500	0	83,050	May 27 04:08 PM
Zaderej Karen L.	Director	May 19 '25	Buy	5.99	5,000	29,950	36,500	May 19 04:06 PM
Zaderej Karen L.	Director	May 16 '25	Buy	5.81	5,000	29,050	31,500	May 19 04:06 PM
Zaderej Karen L.	Director	May 15 '25	Buy	5.47	5,000	27,350	26,500	May 15 04:06 PM
Zaderej Karen L.	Director	May 14 '25	Buy	5.42	5,000	27,100	21,500	May 15 04:06 PM
Elston George	Chief Financial Officer	Feb 09 '25	Option Exercise	0.00	5,834	0	75,550	Feb 11 06:19 PM
Lurker Nancy	Director	Feb 09 '25	Option Exercise	0.00	20,000	0	205,436	Feb 11 06:19 PM
Duker Jay S.	President and CEO	Feb 09 '25	Option Exercise	0.00	7,000	0	79,706	Feb 11 06:19 PM
Elston George	Chief Financial Officer	Jan 06 '25	Option Exercise	0.00	15,285	0	73,374	Jan 07 04:04 PM
Elston George	Chief Financial Officer	Jan 05 '25	Option Exercise	0.00	15,000	0	63,356	Jan 07 04:04 PM
Lurker Nancy	Director	Jan 06 '25	Option Exercise	0.00	75,134	0	185,436	Jan 07 04:04 PM
Lurker Nancy	Director	Jan 05 '25	Option Exercise	0.00	12,667	0	110,302	Jan 07 04:04 PM
Landis John B.	Director	Jan 05 '25	Option Exercise	0.00	10,000	0	21,400	Jan 07 04:04 PM
Duker Jay S.	President and CEO	Jan 06 '25	Option Exercise	0.00	20,794	0	78,814	Jan 07 04:03 PM
Duker Jay S.	President and CEO	Jan 05 '25	Option Exercise	0.00	30,000	0	68,027	Jan 07 04:03 PM
ANTHONY P. ADAMIS	Director	Oct 23 '24	Proposed Sale	10.04	67,100	673,355		Oct 23 04:34 PM
David R. Guyer	Former Director	Oct 14 '24	Proposed Sale	8.92	36,975	329,817		Oct 15 11:58 AM
DICICCO WENDY F	Director	Aug 20 '24	Buy	7.79	2,567	19,997	9,967	Aug 21 04:32 PM
ANDO GORAN	Director	Aug 21 '24	Buy	7.95	5,000	39,750	13,150	Aug 21 04:01 PM
Zaderej Karen L.	Director	Aug 19 '24	Buy	7.98	12,500	99,750	16,500	Aug 21 04:01 PM
Lurker Nancy	Director	Aug 16 '24	Buy	7.88	3,173	25,003	97,635	Aug 20 04:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EYPT

EyePoint Pharmaceuticals Inc

Upgrade your FINVIZ experience